These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

767 related items for PubMed ID: 19466975

  • 21. Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boiocchi L, Vener C, Savi F, Bonoldi E, Moro A, Fracchiolla NS, Iurlo A, Deliliers GL, Coggi G, Bosari S, Gianelli U.
    J Clin Pathol; 2011 Mar; 64(3):226-31. PubMed ID: 21217153
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].
    Kim JT, Cho YG, Choi SI, Lee YJ, Kim HR, Jang SJ, Moon DS, Park YJ, Park G.
    Korean J Lab Med; 2010 Dec; 30(6):567-74. PubMed ID: 21157140
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].
    Borovecki A, Skrtić A, Paro MM, Lasan R, Dominis M.
    Acta Med Croatica; 2011 Sep; 65 Suppl 1():31-6. PubMed ID: 23126027
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
    Macedo LC, Santos BC, Pagliarini-e-Silva S, Pagnano KB, Rodrigues C, Quintero FC, Ferreira ME, Baraldi EC, Ambrosio-Albuquerque EP, Sell AM, Visentainer JE.
    Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
    [Abstract] [Full Text] [Related]

  • 30. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Pătrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA.
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2V617F mutation.
    Fan W, Cao W, Shi J, Gao F, Wang M, Xu L, Wang F, Li Y, Guo R, Bian Z, Li W, Jiang Z, Ma W.
    Ann Hematol; 2023 Jul; 102(7):1745-1759. PubMed ID: 37233774
    [Abstract] [Full Text] [Related]

  • 36. Proteolytic matrix metallopeptidases and inhibitors in BCR-ABL1-negative myeloproliferative neoplasms: correlation with JAK2 mutation status.
    Vadikolia CM, Tsatalas C, Anagnostopoulos K, Trypsianis G, Pantelidou D, Bazdiara I, Anastasiadis A, Spanoudakis E, Kotsianidis I, Margaritis D, Kortsaris A, Bourikas G.
    Acta Haematol; 2011 Jul; 126(1):54-62. PubMed ID: 21474922
    [Abstract] [Full Text] [Related]

  • 37. VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Gianelli U, Vener C, Raviele PR, Savi F, Somalvico F, Calori R, Iurlo A, Radaelli F, Fermo E, Bucciarelli P, Bori S, Coggi G, Deliliers GL.
    Am J Clin Pathol; 2007 Dec; 128(6):966-73. PubMed ID: 18024322
    [Abstract] [Full Text] [Related]

  • 38. The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.
    Ohyashiki JH, Yoneta M, Hisatomi H, Iwabuchi T, Umezu T, Ohyashiki K.
    BMC Med Genet; 2012 Jan 17; 13():6. PubMed ID: 22251709
    [Abstract] [Full Text] [Related]

  • 39. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
    Mahjoub S, Baccouche H, Sahnoun M, Kaabi H, Manai Z, Slama H, Ben Romdhane N.
    Tunis Med; 2015 Jul 17; 93(7):474-7. PubMed ID: 26757507
    [Abstract] [Full Text] [Related]

  • 40. JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.
    Oku S, Takenaka K, Kuriyama T, Shide K, Kumano T, Kikushige Y, Urata S, Yamauchi T, Iwamoto C, Shimoda HK, Miyamoto T, Nagafuji K, Kishimoto J, Shimoda K, Akashi K.
    Br J Haematol; 2010 Aug 17; 150(3):334-44. PubMed ID: 20553273
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.